The Manufacturers Life Insurance Company Purchases New Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS)

The Manufacturers Life Insurance Company purchased a new position in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 129,700 shares of the biopharmaceutical company’s stock, valued at approximately $204,000. The Manufacturers Life Insurance Company owned about 0.20% of Regulus Therapeutics as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in Regulus Therapeutics by 158.4% during the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock worth $2,132,000 after buying an additional 453,784 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Regulus Therapeutics in the 2nd quarter valued at about $352,000. Tyche Wealth Partners LLC raised its holdings in shares of Regulus Therapeutics by 920.6% in the 3rd quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock valued at $167,000 after purchasing an additional 95,694 shares during the period. Rhumbline Advisers acquired a new stake in Regulus Therapeutics in the 2nd quarter valued at about $136,000. Finally, Renaissance Technologies LLC grew its holdings in Regulus Therapeutics by 56.4% during the second quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 42,600 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on RGLS. StockNews.com raised Regulus Therapeutics to a “sell” rating in a research report on Tuesday, September 17th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research note on Monday, November 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.80.

Regulus Therapeutics Trading Up 3.8 %

NASDAQ:RGLS opened at $1.64 on Tuesday. The stock has a 50 day simple moving average of $1.53 and a 200 day simple moving average of $1.71. Regulus Therapeutics Inc. has a 1-year low of $1.08 and a 1-year high of $3.79. The stock has a market cap of $107.42 million, a P/E ratio of -1.54 and a beta of 1.61.

Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). As a group, sell-side analysts forecast that Regulus Therapeutics Inc. will post -0.88 EPS for the current year.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.